AR083221A1 - PROCESS TO PRODUCE NUCLEOSID DIALYLPHOSPHOTRIESTERS THROUGH ENZYMATIC TRANSESTERIFICATION AND DEPROTECTION OF THE SAME TO PRODUCE MONOPHOSPHATE NUCLEOSIDS - Google Patents

PROCESS TO PRODUCE NUCLEOSID DIALYLPHOSPHOTRIESTERS THROUGH ENZYMATIC TRANSESTERIFICATION AND DEPROTECTION OF THE SAME TO PRODUCE MONOPHOSPHATE NUCLEOSIDS

Info

Publication number
AR083221A1
AR083221A1 ARP110103609A ARP110103609A AR083221A1 AR 083221 A1 AR083221 A1 AR 083221A1 AR P110103609 A ARP110103609 A AR P110103609A AR P110103609 A ARP110103609 A AR P110103609A AR 083221 A1 AR083221 A1 AR 083221A1
Authority
AR
Argentina
Prior art keywords
nucleoside
phosphotriester
produce
dialkyl
monophosphate
Prior art date
Application number
ARP110103609A
Other languages
Spanish (es)
Inventor
Adolfo Marcelo Iribarren
Elizabeth Sandra Lewkowicz
Lucas Andres Dettorre
Original Assignee
Univ Nac Quilmes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nac Quilmes filed Critical Univ Nac Quilmes
Publication of AR083221A1 publication Critical patent/AR083221A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001Phosphodiesterase I (3.1.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/08Phosphoric triester hydrolases (3.1.8)
    • C12Y301/08001Aryldialkylphosphatase (3.1.8.1), i.e. paraoxonase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un proceso para producir un dialquilfosfotriéster de nucleósido, donde el proceso comprende la reacción de un nucleósido con un compuesto fosfotriéster activado como un dador de fosfato en presencia de una enzima fosfotriesterasa.Reivindicación 12: Un proceso para producir un nucleósido monofosfato monoéster, el proceso que comprende las etapas de: a) conducir la transesterificación enzimática de acuerdo con la reivindicación 1, mediante la reacción de un nucleósido con un compuesto fosfotriéster activado como un dador de fosfato en presencia de una enzima fosfotriesterasa, b) eliminar los grupos alquilo del dialquilfosfotriéster de nucleósido obtenido en la etapa (a) mediante reacción con un agente químico seleccionado del grupo de reactivos básicos inorgánicos u orgánicos, reactivos ácidos inorgánicos u orgánicos, tioalcoholes y reactivos de hidrogenación, o c) eliminar los grupos alquilo del dialquilfosfotriéster de nucleósido obtenido en la etapa (a) mediante hidrólisis de acuerdo con las siguientes etapas: i) incubar el dialquilfosfotriéster de nucleósido en presencia de una enzima fosfotriesterasa, ii) incubar el alquilfosfodiéster de nucleósido de la etapa (i) en presencia de una enzima fosfodiesterasa, y recoger el nucleósido monofosfato de la mezcla de reacción.Claim 1: A process for producing a nucleoside dialkyl phosphotriester, wherein the process comprises the reaction of a nucleoside with an activated phosphotriester compound as a phosphate donor in the presence of a phosphotriesterase enzyme. Claim 12: A process for producing a monoester monophosphate nucleoside, the process comprising the steps of: a) conducting the enzymatic transesterification according to claim 1, by reacting a nucleoside with an activated phosphotriester compound as a phosphate donor in the presence of a phosphotriesterase enzyme, b) eliminating the alkyl groups of the nucleoside dialkyl phosphotriester obtained in step (a) by reaction with a chemical agent selected from the group of basic inorganic or organic reagents, inorganic or organic acid reagents, thioalcohols and hydrogenation reagents, or c) eliminating the alkyl groups of the nucleoside dialkyl phosphotriester obtained and n step (a) by hydrolysis according to the following steps: i) incubating the nucleoside dialkyl phosphotriester in the presence of a phosphotriesterase enzyme, ii) incubating the nucleoside alkyl phosphodiester of step (i) in the presence of a phosphodiesterase enzyme, and collect the nucleoside monophosphate from the reaction mixture.

ARP110103609A 2010-09-29 2011-09-29 PROCESS TO PRODUCE NUCLEOSID DIALYLPHOSPHOTRIESTERS THROUGH ENZYMATIC TRANSESTERIFICATION AND DEPROTECTION OF THE SAME TO PRODUCE MONOPHOSPHATE NUCLEOSIDS AR083221A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38767010P 2010-09-29 2010-09-29

Publications (1)

Publication Number Publication Date
AR083221A1 true AR083221A1 (en) 2013-02-06

Family

ID=44773066

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103609A AR083221A1 (en) 2010-09-29 2011-09-29 PROCESS TO PRODUCE NUCLEOSID DIALYLPHOSPHOTRIESTERS THROUGH ENZYMATIC TRANSESTERIFICATION AND DEPROTECTION OF THE SAME TO PRODUCE MONOPHOSPHATE NUCLEOSIDS

Country Status (2)

Country Link
AR (1) AR083221A1 (en)
WO (1) WO2012041965A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117095C2 (en) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. NUCLEOSIDE COMPOUND OR PHARMACEUTICALALLY SUITABLE SALT
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
EP3055319A4 (en) 2013-10-11 2018-01-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
EA201890454A1 (en) 2015-08-06 2018-07-31 Чимерикс, Инк. PYRROPHYRIMIDINE NUCLEOSIDE AND THEIR ANALOGUES THAT CAN BE USED AS ANTI-VIRUS MEANS
DK3512863T3 (en) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2β-substituted-N6-substituted purine nucleotides for the treatment of RNA virus
CN115477679A (en) 2017-02-01 2022-12-16 阿堤亚制药公司 Nucleotide hemisulfates for the treatment of hepatitis C virus
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20240022574A (en) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. Favorable anti-HCV combination therapy
TW202400134A (en) 2022-03-15 2024-01-01 美商羅米醫療公司 Compounds and methods for treating disease
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756315A (en) 1989-12-05 1998-05-26 Kyowa Hakko Kogyo Co., Ltd. Inosine-guanosine kinase
US6987008B1 (en) 1999-09-03 2006-01-17 Ajinomoto Co., Inc. Variant nucleoside-5′-phosphate producing enzyme
AUPR502301A0 (en) * 2001-05-15 2001-06-07 Commonwealth Scientific And Industrial Research Organisation Phosphotriesterase from Agrobacterium radiobacter P230

Also Published As

Publication number Publication date
WO2012041965A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
AR083221A1 (en) PROCESS TO PRODUCE NUCLEOSID DIALYLPHOSPHOTRIESTERS THROUGH ENZYMATIC TRANSESTERIFICATION AND DEPROTECTION OF THE SAME TO PRODUCE MONOPHOSPHATE NUCLEOSIDS
CL2020002805A1 (en) Method to identify a modulator of a biological system; method to identify a modulator of a disease process (divisional 201302526)
CO6551739A2 (en) METHODS TO IMPROVE THE EFFECTIVENESS OF SIMULTANEOUS SACRIFICATION AND FEMENTATION REACTIONS
AR122864A2 (en) LIPASE VARIANTS AND POLYNUCLEOTIDES ENCODING THEM
PE20121436A1 (en) METHOD FOR THE ENZYMATIC PRODUCTION OF 3-HYDROXY-3-METHYLBUTYRIC ACID FROM ACETONE AND ACETYL-COA
BR112015006255A2 (en) METHODS FOR THE PRODUCTION OF CHEMICAL PRODUCTS AND DERIVATIVES THEREOF
NZ728437A (en) Methods for increasing cas9-mediated engineering efficiency
EP2385955A4 (en) MODIFIED ANTIBODY COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
MX2019008780A (en) Detergent compositions.
EA202191796A2 (en) METHOD FOR SITE-SPECIFIC ENZYMATIC LABELING OF NUCLEIC ACIDS IN VITRO BY INTRODUCING NON-NATURALLY NUCLEOTIDES
AR084774A1 (en) NUCLEIC ACID MOLECULES THAT CONFERENCE RESISTANCE TO COLEOPTER PESTS
MX2016007029A (en) PROCESS FOR THE PRODUCTION OF BIOMASS SUGARS.
CL2013000427A1 (en) Method for extracting high purity lithium from lithium carrier solution by electrolysis which comprises preparing aqueous lithium phosphate solution from lithium carrier solution by adding phosphorus supplier material, extracting lithium from said solution using electrolytic device.
ECSP099342A (en) PURINS AS INHIBITORS OF THE PKC THETA
BR112013030262A2 (en) hydroformylation process
BR112017018063A2 (en) process for preparing a compound, use of a compound, and, composition
EA201270463A1 (en) METHOD AND REAGENTS FOR INHIBITING OR REDUCING THE FORMATION OF DEPOSITS ON THE WALLS OF THE PIPELINES DURING THE PRODUCTION OF PHOSPHORIC ACID
BR112012030528A2 (en) process and microorganisms for lipid production
BR112014002068A2 (en) method for preparing functionalized graphene
MX2015004415A (en) ORGANIC PHOSPHORUS COMPOUNDS FOR FLAM RETARDANT POLYURETHANE FOAMS.
MY181657A (en) Catalyst for hydrogenolysis of polyhydric alcohol and method for producing 1,3-propanediol using catalyst for hydrogenolysis of polyhydric alcohol
BR112018017316A2 (en) compounds and methods for the synthesis of 5- (n-protected-tryptaminocarboxyamide) -2'-deoxyuridine phosphoramidate for incorporation into a nucleic sequence
BR112015030815A2 (en) phosphorylated polymers
BR112021019657A2 (en) Method to produce knock-in cell
EP4249603A3 (en) Design and development of novel detergents for use in pcr systems

Legal Events

Date Code Title Description
FB Suspension of granting procedure